Patents by Inventor Randall K. Ribaudo

Randall K. Ribaudo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta2 microglobulin fusion proteins and high affinity variants
    Publication number: 20040091492
    Abstract: &bgr;2-microglobulin fusion proteins and modified forms of &bgr;2-microglobulin are disclosed. The fusion proteins are shown to incorporate onto the surface of MHC I expressing mammalian cells and to cause an increased cytotoxic T-cell response to antigens presented by such cells. The fusion proteins are useful in methods of tumor therapy. Modified forms of human &bgr;2-microglobulin, particularly a form having a serine to valine transition at amino acid position 55 of the mature protein are shown to have an enhanced affinity for MHC I heavy chain, and are useful both in the disclosed fusion proteins and as a vaccine adjuvant where enhanced cytotoxic T-cell response is desired.
    Type: Application
    Filed: December 2, 2003
    Publication date: May 13, 2004
    Applicant: The Government of the USA as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Randall K. Ribaudo, Michael Shields
  • &bgr;2 microglobulin fusion proteins and high affinity variants
    Patent number: 6682741
    Abstract: &bgr;2-microglobulin fusion proteins and modified forms of &bgr;2-microglobulin are disclosed. The fusion proteins are shown to incorporate onto the surface of MHC I expressing mammalian cells and to cause an increased cytotoxic T-cell response to antigens presented by such cells. The fusion proteins are useful in methods of tumor therapy. Modified forms of human &bgr;2-microglobulin, particularly a form having a serine to valine transition at amino acid position 55 of the mature protein are shown to have an enhanced affinity for MHC I heavy chain, and are useful both in the disclosed fusion proteins and as a vaccine adjuvant where enhanced cytotoxic T-cell response is desired.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: January 27, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Randall K. Ribaudo, Michael Shields